{"transactions":[{"id":1428276,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-20T18:23:17.000Z","date":"2024-08-16","kind":"purchase","planned":false,"acquired":true,"shares":428,"price":2.9768,"value":1274.0704,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":2117213,"source":{"system":"sec-edgar","filing":"0001437749-24-027344","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924027344/rdgdoc.xml","form_type":"4"}},{"id":1428275,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-20T18:23:17.000Z","date":"2024-08-16","kind":"purchase","planned":false,"acquired":true,"shares":5390,"price":2.93,"value":15792.7,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":2116785,"source":{"system":"sec-edgar","filing":"0001437749-24-027344","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924027344/rdgdoc.xml","form_type":"4"}},{"id":1448359,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-26T14:50:20.000Z","date":"2024-07-25","kind":"purchase","planned":false,"acquired":true,"shares":30227,"price":3.0533,"value":92292.0991,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":2111395,"source":{"system":"sec-edgar","filing":"0001437749-24-023533","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924023533/rdgdoc.xml","form_type":"4"}},{"id":1448358,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-26T14:50:20.000Z","date":"2024-07-24","kind":"purchase","planned":false,"acquired":true,"shares":7056,"price":3.1573,"value":22277.9088,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":2081168,"source":{"system":"sec-edgar","filing":"0001437749-24-023533","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924023533/rdgdoc.xml","form_type":"4"}},{"id":1448357,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-26T14:50:20.000Z","date":"2024-07-24","kind":"purchase","planned":false,"acquired":true,"shares":17800,"price":3.1795,"value":56595.1,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":2074112,"source":{"system":"sec-edgar","filing":"0001437749-24-023533","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924023533/rdgdoc.xml","form_type":"4"}},{"id":1448356,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-26T14:50:20.000Z","date":"2024-07-24","kind":"purchase","planned":false,"acquired":true,"shares":165000,"price":3.2,"value":528000.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":2056312,"source":{"system":"sec-edgar","filing":"0001437749-24-023533","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924023533/rdgdoc.xml","form_type":"4"}},{"id":1455603,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-11","kind":"purchase","planned":false,"acquired":true,"shares":94537,"price":3.4516,"value":326303.9092,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1891312,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}},{"id":1455602,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-10","kind":"purchase","planned":false,"acquired":true,"shares":21963,"price":3.4632,"value":76062.2616,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1796775,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}},{"id":1455601,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-10","kind":"purchase","planned":false,"acquired":true,"shares":33500,"price":3.4647,"value":116067.45,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1774812,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}},{"id":1455600,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-09","kind":"purchase","planned":false,"acquired":true,"shares":16917,"price":3.4339,"value":58091.2863,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1741312,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}},{"id":1455599,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-08","kind":"purchase","planned":false,"acquired":true,"shares":17600,"price":3.535,"value":62216.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1724395,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}},{"id":1455598,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-08","kind":"purchase","planned":false,"acquired":true,"shares":29892,"price":3.4114,"value":101973.5688,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1706795,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}},{"id":1455597,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-05","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":3.41,"value":17050.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1676903,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}},{"id":1455596,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-05","kind":"purchase","planned":false,"acquired":true,"shares":23326,"price":3.4303,"value":80015.1778,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1671903,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}},{"id":1455595,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":15494,"kind":"organization","name":"Janus Henderson Group Ltd.","symbol":"JHG","position":1,"cik":"0001274173","reported_name":"JANUS HENDERSON GROUP PLC","relationship":{"ten_percent_owner":true}},{"id":88203,"kind":"organization","name":"Janus Henderson Biotech Innovation Master Fund Ltd","position":2,"cik":"0002030299","reported_name":"Janus Henderson Biotech Innovation Master Fund Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-12T23:38:10.000Z","date":"2024-07-03","kind":"purchase","planned":false,"acquired":true,"shares":166042,"price":3.5507,"value":589565.3294,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the \"Fund\"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any."}],"balance_after":1648577,"source":{"system":"sec-edgar","filing":"0001437749-24-022708","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000143774924022708/rdgdoc.xml","form_type":"4"}}]}